Aurobindo Pharma released a statement today stating that they have entered into an exclusive licensing agreement with Covaxx to develop, commercialize & manufacture the first multitope peptide (a synthetic protein) UB-612 vaccine to help fight Coronavirus for India and United Nations Children’s Fund (UNICEF).
Aurobindo will manufacture 220 million doses in their Hyderabad facility and will be building another additional facility to manufacture 480 million doses by June 2021.